Replies to post #25191 on Lifeline Biotechnologies Inc (LLBO)

[Chaka]

ALL THESE YEARS OF PATIENTLY WAITING..
2018 WILL BE LLBO BREAKOUT YEAR.
( LOOK @ ALR* )
SAME PPS: .0020- SHOT UP .145 IN ONE DAY TRADING!
Yes, both SS are different.
But, we're targeting breast cancer DETECTION.
I EXPECT US TO REACH @ LEAST 2-3 COPPERS IN A DAY ONCE NEWS OF FDA APPROVE CIRCULATE.
glta.

[JustGoDeep]

Umm, About that Dilution Here is Proof

https://pitchbook.com/profiles/company/54937-18

LLBO no longer has 40% ownership as of this latest round of dilution.

Just the Facts.

Now do the Math.

[JustGoDeep]

And Yes the Clinical's are not EVEN Going-on-Right-Now

Please read first red highlighted area. "WILL BE RESUMED"

Second, once they do resume they could "POSSIBLY COMPLETED TATER THIS YEAR ?"

Please notice the question mark.

Subsequently, Cyrcadia, Inc. licensed Cyrcadia Asia to further develop and finance product upgrades to Cyrcadia, Inc.’s basic capabilities. The increased capabilities include updated and current state of the art technology and efficiencies. These upgrades are nearing completion and product is forecast, by vendors, to be market ready and available by mid-2018. The clinical trials Cyrcadia, Inc. has been conducting at El Camino Hospital and Ohio State University’s Cancer Center, were approximately one-third completed, will be resumed upon product availability, and continued until completion. There have been several positive outcomes derived from the one third completion of the trials, those outcomes, which cannot be described here due to FDA regulations, indicate the trials may be able to be completed in a shorter period of time than originally estimated, possibly completed later this year?